Auris Medical Holding (EARS) Reports In-Line Q2 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Auris Medical Provides Business Update and Reports Second Quarter 2016 Financial Results
August 18, 2016 7:24 AM EDTTACTT2 trial with KeyzilenTM for acute inner ear tinnitus did not meet efficacy endpoints Top-line results from TACTT3 trial with KeyzilenTM expected in the fourth quarter of 2016 AM-111 Phase 3 program for acute inner ear hearing loss is ongoing Conference call today at 8 am Eastern Time
ZUG, Switzerland, Aug. 18, 2016 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today provided a business update... More
Auris Medical Reports Top-Line Results from TACTT2 Trial with Keyzilen in Acute Inner Ear Tinnitus
August 18, 2016 6:28 AM EDTTACTT2 trial did not meet its co-primary efficacy endpoints Top-line results from the Phase 3 TACTT3 trial expected in the fourth quarter of 2016 Second quarter 2016 financial results and conference call scheduled for today
ZUG, Switzerland, Aug. 18, 2016 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced top-line results from the Phase 3 TACTT2 trial with KeyzilenTM (AM-101) in acute inner ear tinnitus. The TACTT2 trial did not meet the two co-primary... More
